Date closed: 12/29/2016
Value: C$60 million
On December 29, 2016, CanniMed Therapeutics Inc., (CMED) a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, successfully completed an initial public offering of its common shares (the Offering) on December 29, 2016. In connection with the Offering, CMED issued 5,000,000 common shares at a price of C$12.00 per common share, resulting in aggregate gross proceeds to CMED of C$60,000,000. CMED's common shares began trading on the Toronto Stock Exchange under the symbol "CMED".
The Offering was made through a syndicate of underwriters led by AltaCorp Capital Inc. and included Canaccord Genuity Corp., Clarus Securities Inc., Mackie Research Capital Corporation and Haywood Securities Inc.BLG represented CMED with a team led by Philippe Tardif that included Andrew Powers, Linda Tu, Colin Cameron-Vendrig, Joseph Di Ponio, Danny Lang, David Wood, Francine Ferrer and Chris Savo.